References
- Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937–951.
- Greenberg P, Cox C, LeBeau MM, . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
- Greenberg PL, Tuechler H, Schanz J, . Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
- Ries C, Loher F, Zang C, . Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999;5:1115–1124.
- Melo Rde CC, Arouca MM, Bigarella CL, . Low expression of tissue inhibitor of metalloproteinase-2 may be associated with high risk myelodysplastic syndrome. Leuk Lymphoma 2013;54:1091–1093.
- Yoshida K, Sanada M, Shiraishi Y, . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64–69.
- Malcovati L, Papaemmanuil E, Bowen DT, . Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118: 6239–6246.
- Bejar R, Stevenson K, Abdel-Wahab O, . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364: 2496–2506.
- List A, Dewald G, Bennett J, . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355: 1456–1465.
- Silverman LR, Demakos EP, Peterson BL, . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–2440.